The Heart Failure Society of America has released a new comprehensive look at HF clinics in the United States. The report includes more than 300 programs that serve approximately 626,000 patients.
“Our analyses could not fully ascribe the effects of semaglutide on cardiovascular disease to known risk factors with any certainty,” one researcher said after exploring years of data. "These results suggest that semaglutide should be considered as a cardiovascular disease reduction drug and not just as a weight loss drug."
AI-based tools are here to stay, but one expert does not see them replacing cardiologists anytime soon. Look at recent trends in radiology, he says, to get a better idea of what cardiology's future may look like.
This latest alert comes after Johnson & Johnson MedTech found that certain devices may require hardware, firmware and/or software updates to address safety concerns.
"I want to be safe, I want to get the vessel open and I don’t want to spend a long time doing it," cardiologist William C. Dixon, MD, explains. "IVL helps me achieve all of those things.”
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/top_stories/public/2024-09/istock-1209664264.jpg.webp?itok=gQInU1vO)
